Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides a varied selection of highly potent anti-FGFR3 recombinant antibodies, precisely produced for use in a variety of immunological tests. These antibodies are developed to be extremely precise and specific, allowing researchers to confidently examine the involvement of FGFR3 in a variety of biological pathways.
FGFR-3 is a member of the fibroblast growth factor receptor family, characterized by a highly conserved amino acid sequence across species. This receptor binds to both acidic and basic fibroblast growth hormones and plays a key role in bone formation and maintenance. Recent studies have identified aberrant FGFR-3 expression in various diseases and cancers, including achondroplasia, bladder cancer, multiple myeloma, and cervical cancer. Consequently, targeting FGFR-3 represents a promising avenue for therapeutic intervention in these conditions.
Fibroblast growth factor receptor 3; FGFR-3; hydroxyaryl-protein kinase; ACH; CD333; CEK2; HSFGFR3EX; tyrosine kinase JTK4; JTK4; HBGFR.
This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia.
Creative Biolabs offers a wide spectrum of recombinant antibodies that target FGFR3, each expertly tailored for accurate identification and neutralization. These antibodies are available in a number of forms and have outstanding specificity and affinity, making them ideal for a wide range of applications.
Table 1. Featured anti-FGFR3 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
PABL-474 | Human Anti-FGFR3 Recombinant Antibody (clone R3Mab) | Human | Human IgG | ELISA |
TAB-064WM | Anti-Human FGFR3 Recombinant Antibody (15D8) | Human | Mouse | Neut, ELISA |
HPAB-0160-YC | Human Anti-FGFR3 Recombinant Antibody (clone PRO-001) | Human, Mouse | Human IgG | FC, FuncS |
VS3-FY2003 | Rabbit Anti-FGFR3 Recombinant Antibody (clone R03-2C7) | Human, Mouse, Rat | Rabbit IgG | WB |
HPAB-0157-YC | Human Anti-FGFR3 Recombinant Antibody (HPAB-0157-YC) | Human | Human IgG | ELISA, IP, WB |
Creative Biolabs is a leading provider of precise anti-FGFR3 recombinant antibodies for cutting-edge research. We produce antibodies with exceptional qualities by integrating complex biotechnological methods with tight quality control. Our skilled scientists are committed to offering trustworthy solutions that support your research goals, covering everything from fundamental biology to medication development.
Fig.1 SDS-PAGE analysis of anti-FGFR3 antibody
(Cat# PABL-474, Creative Biolabs).
Fig.2 WB analysis of anti-FGFR3 antibody
(Cat# PABL-474, Creative Biolabs).
Fig.3 WB analysis of anti-FGFR3 antibody
(Cat# VS3-FY2003, Creative Biolabs).
Fig.4 WB analysis of anti-FGFR3 antibody
(Cat# VS3-FY2003, Creative Biolabs).
Fig.5 ELISA analysis of anti-FGFR3 antibody
(Cat# TAB-064WM, Creative Biolabs).
Fig.6 Dot Blot analysis of anti-FGFR3 antibody
(Cat# TAB-064WM, Creative Biolabs).
Creative Biolabs employs cutting-edge recombinant antibody manufacturing technology designed exclusively for producing anti-FGFR3 antibodies. Our novel genetic engineering technologies enable the quick and high-quality synthesis of antibodies, ensuring a constant and trustworthy supply for all of your research requirements.
Featured Anti-FGFR3 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-FGFR3 recombinant antibody production.
Fig.8 Gram-scale anti-FGFR3 recombinant antibody production.
Creative Biolabs provides a wide choice of superior anti-FGFR3 recombinant antibodies customized to the unique requirements of researchers worldwide. Our antibodies are offered in a variety of forms, guaranteeing flexibility and efficacy across a broad range of scientific uses.
Fig.9 Full-length anti-FGFR3 recombinant antibody production and modalities.
Table 2. Public drug targeting FGFR3.
Company | Research Phase | Classification | Condition |
Novartis Europharm Limited Novartis Farma S.P.A. Novartis |
Approved, Phase IV | Kinase Inhibitor |
Advanced renal cell carcinoma Advanced soft tissue sarcoma Advanced thyroid cancer |
Ariad Pharmaceuticals Incyte Biosciences Distribution B.V. Takeda Pharma A/S |
Approved, Phase III | Kinase Inhibitor |
Accelerated phase chronic myeloid leukemia Acute lymphoblastic leukemia Chronic phase chronic myeloid leukemia Blast phase chronic myeloid leukemia |
Eisai Limited | Approved, Phase IV | Kinase Inhibitor |
Differentiated Thyroid Cancer (DTC) Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Endometrial Carcinoma |
Eugia Pharma (Malta) Limited Accord Healthcare, S.L.U. Boehringer Ingelheim Boehringer Ingelheim Pharmaceuticals, Inc. |
Approved, Phase IV |
Antifibrotic Agents Kinase Inhibitor |
Decreased pulmonary function Idiopathic pulmonary fibrosis Chronic progressive fibrosing interstitial lung disease Locally advanced non-small cell lung carcinoma (nsclc) |
Incyte Biosciences Distribution B.V. Incyte Corporation |
Approved, Phase III | Kinase Inhibitor |
Refractory myeloid/lymphoid neoplasms with fgfr1 rearrangement Unresectable, locally advanced cholangiocarcinomas |
Qed Therapeutics, Inc. | Approved, Phase III | Kinase Inhibitor | Advanced bile duct cancer in adults |
Taiho Pharma Netherlands Bv Taiho Pharmaceutical Co., Ltd. |
Approved, Phase III | Kinase Inhibitor | Intrahepatic cholangiocarcinoma in previously treated adults |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
At Creative Biolabs, we are committed to providing exceptional customer service and high-quality anti-FGFR3 recombinant antibodies. Our team of professionals is committed to helping you pick the best antibodies for your individual requirements and ensuring your total satisfaction. Contact us today to find out how our products and services may help you reach your research goals.